Michael Albeck
Overview
Explore the profile of Michael Albeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaouat A, Kalechman Y, Hay O, Manoim J, Lantner T, Niderberg E, et al.
Int J Biol Sci
. 2024 Sep;
20(11):4407-4423.
PMID: 39247817
Various cancer treatment approaches that inhibit the activity of the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis, a key player in tumor immune evasion, have been developed. We show that the...
2.
Silberman A, Albeck M, Sredni B, Albeck A
Inorg Chem
. 2016 Oct;
55(21):10847-10850.
PMID: 27726342
Since its first crystallization, the aqueous structure of the tellurium-containing experimental drug AS-101 has never been studied. We show that, under the aqueous conditions in which it is administered, AS-101...
3.
Danoch H, Kalechman Y, Albeck M, Longo D, Sredni B
Mol Cancer Res
. 2014 Oct;
13(3):411-22.
PMID: 25351768
Unlabelled: Cancer cell resistance to chemotherapy is a major concern in clinical oncology, resulting in increased tumor growth and decreased patient survival. Manipulation of apoptosis has emerged as a new...
4.
Halpert G, Eitan T, Voronov E, Apte R, Rath-Wolfson L, Albeck M, et al.
J Biol Chem
. 2014 Apr;
289(24):17215-27.
PMID: 24764299
Inflammatory bowel diseases (IBDs) are a group of idiopathic, chronic immune-mediated diseases characterized by an aberrant immune response, including imbalances of inflammatory cytokine production and activated innate and adaptive immunity....
5.
Layani-Bazar A, Skornick I, Berrebi A, Pauker M, Noy E, Silberman A, et al.
Cancer Res
. 2014 Apr;
74(11):3092-103.
PMID: 24699624
Interaction between the integrin VLA-4 on acute myelogenous leukemia (AML) cells with stromal fibronectin is a decisive factor in chemotherapeutic resistance. In this study, we provide a rationale for a...
6.
Brodsky M, Halpert G, Albeck M, Sredni B
J Inflamm (Lond)
. 2010 Mar;
7(1):3.
PMID: 20205748
Background: LPS-activated macrophages produce mediators which are involved in inflammation and tissue injury, and especially those associated with endotoxic shock. The non toxic tellurium compound ammonium tri-chloro(dioxoethylene-O,O'-)tellurate, AS101, has been...
7.
Brodsky M, Hirsh S, Albeck M, Sredni B
J Hepatol
. 2009 Jul;
51(3):491-503.
PMID: 19595469
Background/aims: Fulminant hepatic failure is a dangerous condition, which occurs when large parts of the liver become damaged beyond repair, and the liver is no longer able to function. This...
8.
Daniel-Hoffmann M, Albeck M, Sredni B, Nitzan Y
Arch Microbiol
. 2009 Jun;
191(8):631-8.
PMID: 19529918
Due to the extensive spread of antibiotic-resistant Klebsiella pneumoniae, the non-toxic immunomodulator, ammonium trichloro (dioxoethylene-o, o') tellurate (AS101), was introduced for the first time in this study. Eleven strains of...
9.
Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N, Sredni B
Exp Hematol
. 2009 Apr;
37(5):593-603.
PMID: 19375650
Objective: We previously showed that the organotellurium compound, ammonium trichloro (dioxyethylene-0-0') tellurate (AS101), has antitumoral activity in multiple myeloma (MM) cell lines. Here, we evaluated the antimyeloma activity of AS101...
10.
Sinuani I, Weissgarten J, Beberashvili I, Rapoport M, Sandbank J, Feldman L, et al.
Nephrol Dial Transplant
. 2009 Mar;
24(8):2328-38.
PMID: 19321762
Background: Compensatory tubular cell hypertrophy following unilateral nephrectomy is a cell cycle-dependent process. Our previous study showed that treatment of unilaterally nephrectomized rats with the immunomodulator AS101 partially inhibits compensatory...